SABCS 2023 | MiRaDor: monitoring MRD using ctDNA in HR+/HER2- early breast cancer

Antonio Llombart-Cussac, MD, PhD, Hospital Arnau de Vilanova, Valencia, Spain, discusses the Phase II MiRaDor study (NCT05708235) which aims to improve the clinical utility of circulating tumor DNA (ctDNA) in monitoring minimal residual disease (MRD) and understand its applicability in high-risk, HR+/HER2- early breast cancer patients. This multicenter, open-label study, non-comparative, trial will select patients with HR+/HER2- early breast cancer at high risk of relapse, patients who have received adjuvant treatment with endocrine therapy for at least 2 years with 3 additional years planned, had no prior treatment with CDK4/6 inhibitors or fulvestrant, and had surgery in the past 5 years for primary breast cancer. The study will analyze ctDNA and patients with positive ctDNA without radiological disease progression will be allocated to one of 4 treatment arms – standard endocrine therapy, giredestrant, giredestrant + abemaciclib, or giredestrant + inavolisib. The primary objective of the study is to evaluate the rate of patients with at least 90% decrease or clearance in ctDNA after 3 months of treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.